<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SCI</title>
	<atom:link href="http://www.stockbloghub.com/tag/sci/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ACOR) Acorda Therapeutics Inks Deal with Medtronic</title>
		<link>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511</link>
		<comments>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:18:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SCI]]></category>
		<category><![CDATA[Service Corporation International]]></category>
		<category><![CDATA[TBI]]></category>
		<category><![CDATA[TrueBlue Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78511</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently entered into a licensing agreement with Medtronic, Inc. (MDT) for AC105. The company acquired worldwide development and commercialization rights to AC105. The Candidate – AC105 Acorda intends to study AC105 as an acute treatment for patients who have suffered neurological trauma, such as spinal cord injury (SCI) and traumatic brain injury (TBI). The candidate has demonstrated neuroprotective properties and improvement of locomotor function in SCI and cognitive function in TBI when therapy was initiated within four hours of injury in preclinical studies. Medtronic has evaluated the candidate in phase I studies conducted with healthy volunteers. Acorda intends to initially conduct phase II studies with the candidate for SCI. Other studies may subsequently be conducted for central nervous system indications like TBI and stroke. AC105 enjoys ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HI) Hillenbrand Customers: Dying to Buy</title>
		<link>http://www.stockbloghub.com/2009/01/22/hi-hillenbrand-customers-dying-to-buy/2273</link>
		<comments>http://www.stockbloghub.com/2009/01/22/hi-hillenbrand-customers-dying-to-buy/2273#comments</comments>
		<pubDate>Thu, 22 Jan 2009 19:44:05 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Personal Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[HI]]></category>
		<category><![CDATA[Hillenbrand]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Matthews International Corpora]]></category>
		<category><![CDATA[MATW]]></category>
		<category><![CDATA[SCI]]></category>
		<category><![CDATA[Service Corp. International]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2273</guid>
		<description><![CDATA[Hillenbrand Customers: Dying to Buy Crass jokes and mortuary humor aside, the search for “recession proof” industries continues. The recent favorite has fallen back to the ultimate recession proof industry: death. Funeral services like casket-maker Hillenbrand (NYSE: HI) provides are products that will always be in demand. While life expectancies have been climbing over the past few decades, they’ll never climb high enough to put off the inevitable. The death rate for the U.S. has been relatively stable over the years. We lose about 8.27 people for every thousand a year. That’s a market of 2.5 million people who needed some sort of funeral services. As the baby boomers age, the amount of Americans over age 65 will grow larger and so will the “target demographic” for funeral services. Companies ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/22/hi-hillenbrand-customers-dying-to-buy/2273/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

